user

Cardiovascular risk factors in outpatients receiving long acting injectable second generation antipsychotics

被引：0
|
作者：
Draghici, A. [1 ]
Manea, M. O. [1 ]
Andor, M. [2 ]
Tomescu, M. C. [2 ]
Dehelean, L. [3 ]
机构：
[1] Psychiat Clin, Psychiat 2, Timisoara, Romania
[2] Univ Med & Pharm Victor Babes Timisoara, Internal Med 1, Timisoara, Romania
[3] Univ Med & Pharm Victor Babes Timisoara, Neurosci, Timisoara, Romania
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2015年 / 25卷
关键词：
D O I：
10.1016/S0924-977X(15)30691-X
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.043
引用
收藏
页码：S504 / S504
页数：1
相关论文
共 50 条
  • [1] Metabolic Risk Factors Among Medicaid Outpatients With Schizophrenia Receiving Second-Generation Antipsychotics
    Bell, Ryan C.
    Farmer, Sharon
    Ries, Richard
    Srebnik, Debra
    [J]. PSYCHIATRIC SERVICES, 2009, 60 (12) : 1686 - 1689
  • [2] Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case
    Galvan, J.
    Nguepy-Keubo, F. R.
    [J]. EUROPEAN PSYCHIATRY, 2023, 66 : S820 - S820
  • [3] New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Citrome, Leslie
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) : 767 - 783
  • [4] Practical guidelines for the use of long-acting injectable second-generation antipsychotics
    Jarema, Marek
    Wichniak, Adam
    Dudek, Dominika
    Samochowiec, Jerzy
    Bienkowski, Przemyslaw
    Rybakowski, Janusz
    [J]. PSYCHIATRIA POLSKA, 2015, 49 (02) : 225 - 241
  • [5] Adverse Effects of Medication and Quality of Life in Patients Receiving Second Generation Antipsychotics: A Comparison of Long Acting Injectable and Oral Therapies
    Saglam Aykut, Demet
    Civil Arslan, Filiz
    Tiryaki, Ahmet
    Ozkorumak, Evrim
    Karakullukcu, Serdar
    [J]. TURK PSIKIYATRI DERGISI, 2017, 28 (01) : 1 - 6
  • [6] Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
    Rasool, Seemab
    Venan, Paster
    [J]. BJPSYCH OPEN, 2021, 7 : S283 - S283
  • [7] Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics
    Sanchez-Martinez, Vanessa
    Romero-Rubio, Dolores
    Jose Abad-Perez, Maria
    Amparo Descalzo-Cabades, Maria
    Alonso-Gutierrez, Sofia
    Salazar-Fraile, Jose
    Montagud, Vicente
    Facila, Lorenzo
    [J]. ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (04) : 379 - 387
  • [8] Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
    Janzen, Donica
    Bolton, James M.
    Leong, Christine
    Kuo, I. fan
    Alessi-Severini, Silvia
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
    Jann, Michael W.
    Penzak, Scott R.
    [J]. CNS DRUGS, 2018, 32 (03) : 241 - 257
  • [10] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
    Lik Hang N. Lee
    Charles Choi
    Abby C. Collier
    Alasdair M. Barr
    William G. Honer
    Ric M. Procyshyn
    [J]. CNS Drugs, 2015, 29 : 975 - 983
12345